Last reviewed · How we verify
Approved Anti-PD-1 Inhibitor
Approved Anti-PD-1 Inhibitor is a Small molecule drug developed by Dynavax Technologies Corporation. It is currently in Phase 1 development. Also known as: nivolumab.
At a glance
| Generic name | Approved Anti-PD-1 Inhibitor |
|---|---|
| Also known as | nivolumab |
| Sponsor | Dynavax Technologies Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Duration of Anti-PD-1 Therapy in Metastatic Melanoma (PHASE3)
- Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study (PHASE2)
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (PHASE3)
- A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) (PHASE2)
- Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients (PHASE2, PHASE3)
- Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer (PHASE2)
- A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer
- Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Approved Anti-PD-1 Inhibitor CI brief — competitive landscape report
- Approved Anti-PD-1 Inhibitor updates RSS · CI watch RSS
- Dynavax Technologies Corporation portfolio CI
Frequently asked questions about Approved Anti-PD-1 Inhibitor
What is Approved Anti-PD-1 Inhibitor?
Approved Anti-PD-1 Inhibitor is a Small molecule drug developed by Dynavax Technologies Corporation.
Who makes Approved Anti-PD-1 Inhibitor?
Approved Anti-PD-1 Inhibitor is developed by Dynavax Technologies Corporation (see full Dynavax Technologies Corporation pipeline at /company/dynavax-technologies-corporation).
Is Approved Anti-PD-1 Inhibitor also known as anything else?
Approved Anti-PD-1 Inhibitor is also known as nivolumab.
What development phase is Approved Anti-PD-1 Inhibitor in?
Approved Anti-PD-1 Inhibitor is in Phase 1.
Related
- Manufacturer: Dynavax Technologies Corporation — full pipeline
- Also known as: nivolumab
- Compare: Approved Anti-PD-1 Inhibitor vs similar drugs
- Pricing: Approved Anti-PD-1 Inhibitor cost, discount & access